

Christian Thiede

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7775144/publications.pdf>

Version: 2024-02-01

337
papers

23,866
citations

12330
69
h-index

9345
143
g-index

344
all docs

344
docs citations

344
times ranked

18325
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1569-1583.	2.5	3
2	Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns. Leukemia, 2022, 36, 80-89.	7.2	12
3	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood, 2022, 139, 87-103.	1.4	82
4	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	7.2	42
5	Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica, 2022, 107, 836-843.	3.5	14
6	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia, 2022, 36, 111-118.	7.2	31
7	The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clinical Colorectal Cancer, 2022, 21, 170-174.	2.3	17
8	Differential impact of <i>IDH1</i> / <i>IDH2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	5.2	17
9	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 2022, 6, 1941-1946.	5.2	21
10	Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3191-3202.	2.5	14
11	Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML. Frontiers in Oncology, 2022, 12, 841608.	2.8	4
12	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. BMC Cancer, 2022, 22, 201.	2.6	14
13	CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. EMBO Molecular Medicine, 2022, 14, e14990.	6.9	14
14	The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell, 2022, 40, 301-317.e12.	16.8	43
15	RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells, 2022, 11, 854.	4.1	3
16	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Advances, 2022, 6, 3294-3303.	5.2	11
17	Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. Frontiers in Oncology, 2022, 12, 862991.	2.8	1
18	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	17.0	17

#	ARTICLE	IF	CITATIONS
19	Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. <i>Cell Stem Cell</i> , 2022, 29, 760-775.e10.	11.1	29
20	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	7.2	8
21	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations – a registry based analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1432-1440.	1.3	7
22	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	2.5	15
23	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	7.2	40
24	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
25	Impact of <i>PPM1D</i> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	4.1	2
26	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	3.7	7
27	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	3.5	14
28	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <i>Blood</i> , 2021, 138, 507-519.	1.4	40
29	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. <i>Nature Cancer</i> , 2021, 2, 527-544.	13.2	37
30	Clonal hematopoiesis and its emerging effects on cellular therapies. <i>Leukemia</i> , 2021, 35, 2752-2758.	7.2	21
31	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	5.2	21
32	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	1.4	305
33	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	2.3	2
34	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 776946.	2.8	1
35	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	3.5	15
36	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46

#	ARTICLE	IF	CITATIONS
37	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020, 34, 1182-1186.	7.2	39
38	The clinical mutasome of core binding factor leukemia. <i>Leukemia</i> , 2020, 34, 1553-1562.	7.2	60
39	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
40	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3-ITD</i> Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	1.6	335
41	Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma. <i>Neoplasia</i> , 2020, 22, 800-808.	5.3	9
42	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	3.5	29
43	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	1.4	85
44	Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020, 136, 1507-1519.	1.4	57
45	Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. <i>Biomarker Research</i> , 2020, 8, 20.	6.8	7
46	Donor-cell leukemia with novel genetic features 2Âyears after sex-mismatched T cell-depleted haploidentical stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 899-901.	1.8	1
47	Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 28.	3.0	12
48	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
49	Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. <i>Current Treatment Options in Oncology</i> , 2020, 21, 8.	3.0	7
50	A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
51	Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association. <i>Leukemia</i> , 2019, 33, 26-36.	7.2	23
52	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
53	Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1625.	3.7	19
54	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 375-385.	1.6	163

#	ARTICLE	IF	CITATIONS
55	Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. <i>Clinical Biochemistry</i> , 2019, 64, 60-63.	1.9	36
56	Characterization of acute myeloid leukemia with del(9q) – Impact of the genes in the minimally deleted region. <i>Leukemia Research</i> , 2019, 76, 15-23.	0.8	16
57	Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & IIIE: a prospective randomized trial. <i>Journal of Gastroenterology</i> , 2019, 54, 388-395.	5.1	19
58	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. <i>Journal of Neuro-Oncology</i> , 2019, 141, 327-335.	2.9	72
59	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	1.4	796
60	Finding small somatic structural variants in exome sequencing data: a machine learning approach. <i>Computational Statistics</i> , 2018, 33, 1145-1158.	1.5	2
61	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1668-1679.	10.7	250
62	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia – Letter. <i>Cancer Research</i> , 2018, 78, 6339-6341.	0.9	3
63	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1187-1190.	5.2	8
64	Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1947-1951.	2.0	4
65	TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study. <i>Clinical Cancer Research</i> , 2018, 24, 5282-5291.	7.0	63
66	Germ line predisposition to myeloid malignancies appearing in adulthood. <i>Expert Review of Hematology</i> , 2018, 11, 625-636.	2.2	5
67	Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. <i>Proteomes</i> , 2018, 6, 11.	3.5	10
68	miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 36.	6.2	16
69	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	7.2	86
70	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2800-2800.	1.4	6
71	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018, 132, 1534-1534.	1.4	1
72	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018, 132, 435-435.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1333-1342.	1.4	57
74	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	1.4	44
75	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. <i>Journal of Neurosurgery</i> , 2017, 127, 438-444.	1.6	48
76	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1361-1372.	1.8	49
77	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia—Lessons Learned from the Prospective BRIDGE Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1491-1497.	2.0	12
78	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
79	Dynamics of epigenetic age following hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, e321-e323.	3.5	34
80	Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. <i>Leukemia</i> , 2017, 31, 1637-1640.	7.2	34
81	Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. <i>Haematologica</i> , 2017, 102, e39-e42.	3.5	2
82	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 69-78.	30.7	192
83	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017, 99, 544-552.	2.2	5
84	BCAT1 restricts H3K9 levels in AML stem cells leading to IDHmut-like DNA hypermethylation. <i>Nature</i> , 2017, 551, 384-388.	27.8	261
85	Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	30
86	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	1.6	299
87	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations. <i>Oncotarget</i> , 2017, 8, 108738-108759.	1.8	14
88	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	1.4	20
89	Lipidomic approach for stratification of acute myeloid leukemia patients. <i>PLoS ONE</i> , 2017, 12, e0168781.	2.5	33
90	Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. <i>Oncotarget</i> , 2017, 8, 109228-109237.	1.8	89

#	ARTICLE	IF	CITATIONS
91	<i>TP53</i> mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 172, 914-922.	2.5	74
92	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001123.	1.2	2
93	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. <i>Cancer</i> , 2016, 122, 3821-3830.	4.1	92
94	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1988-1996.	2.0	40
95	ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. <i>Nature Communications</i> , 2016, 7, 11733.	12.8	45
96	GFI1 as a novel prognostic and therapeutic factor for AML/MDS. <i>Leukemia</i> , 2016, 30, 1237-1245.	7.2	37
97	Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 462-469.	2.0	74
98	Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 782-788.	7.2	23
99	Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. <i>Leukemia</i> , 2016, 30, 261-267.	7.2	26
100	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. <i>Leukemia</i> , 2016, 30, 555-561.	7.2	47
101	Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden. <i>Leukemia</i> , 2016, 30, 517-520.	7.2	9
102	Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2869-2869.	1.4	0
103	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016, 128, 2815-2815.	1.4	1
104	Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. <i>Haematologica</i> , 2015, 100, e93-e96.	3.5	15
105	MN1-Flt1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. <i>Oncogenesis</i> , 2015, 4, e179-e179.	4.9	11
106	Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. <i>Transfusion</i> , 2015, 55, 2855-2863.	1.6	29
107	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e122-e124.	3.5	20
108	Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. <i>Leukemia</i> , 2015, 29, 1060-1068.	7.2	35

#	ARTICLE	IF	CITATIONS
109	Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. <i>Annals of Hematology</i> , 2015, 94, 557-563.	1.8	7
110	Allogeneic Stem-Cell Transplantation in Patients With <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-410.	1.6	74
111	MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. <i>Experimental Hematology</i> , 2015, 43, 794-802.e4.	0.4	19
112	Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?. <i>Annals of Hematology</i> , 2015, 94, 1363-1371.	1.8	33
113	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	10.7	347
114	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. <i>Leukemia</i> , 2015, 29, 1942-1945.	7.2	18
115	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/PATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	1.4	104
116	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 912-912.	1.4	5
117	Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 38804-38815.	1.8	14
118	Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience. <i>Blood</i> , 2015, 126, 3817-3817.	1.4	0
119	Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter?. <i>Blood</i> , 2015, 126, 1309-1309.	1.4	0
120	Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial. <i>Blood</i> , 2015, 126, 222-222.	1.4	8
121	Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2008-2008.	1.4	0
122	Allogeneic SCT in Multiple Myeloma: Limited Predictive Value of Chimerism Analysis for heralding Relapse/Progression Due to Extramedullary Disease. <i>Blood</i> , 2015, 126, 4396-4396.	1.4	0
123	Mutations of cMYC Exon 2 Are a Rare but Recurrent Abnormality in Adult Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1408-1408.	1.4	0
124	Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2014, 28, 1552-1555.	7.2	56
125	Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2080-2082.	1.5	11
126	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. <i>Annals of Hematology</i> , 2014, 93, 279-285.	1.8	21

#	ARTICLE	IF	CITATIONS
127	Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. <i>Blood</i> , 2014, 123, 894-904.	1.4	133
128	Low frequency of calreticulin mutations in MDS patients. <i>Leukemia</i> , 2014, 28, 1933-1934.	7.2	6
129	Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2014, 4, e218-e218.	6.2	254
130	Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e247-e248.	3.5	7
131	Clonal Hematopoiesis in AML Patients in Hematological CR Is Present in Many Patients with Intermediate Risk AML and Is Associated with a High Prevalence of DNMT3A gene Mutations. <i>Blood</i> , 2014, 124, 121-121.	1.4	9
132	Targeted Resequencing of MLL-PTD Positive AML Patients Reveals a High Prevalence of Co-Occurring Mutations in Epigenetic Regulator Genes. <i>Blood</i> , 2014, 124, 1035-1035.	1.4	0
133	Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4626-4626.	1.4	0
134	Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease. <i>Blood</i> , 2014, 124, 2384-2384.	1.4	0
135	Decisions Taken in Children and Adolescents with Chronic Myeloid Leukemia (CML) at Failure of Imatinib Treatment. <i>Blood</i> , 2014, 124, 1798-1798.	1.4	0
136	Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL). <i>Blood</i> , 2014, 124, 946-946.	1.4	4
137	Prediction of Hematopoietic Stem Cell Yield after Mobilization with G-CSF in Healthy Unrelated Donors. <i>Blood</i> , 2014, 124, 1128-1128.	1.4	0
138	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	27.0	1,284
139	Sex and Body Mass Index but Not CXCL12 801A/G Polymorphism Determine the Efficacy of Hematopoietic Cell Mobilization: A Study in Healthy Volunteer Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1517-1521.	2.0	19
140	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3110-3118.	1.6	290
141	Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. <i>Experimental Hematology</i> , 2013, 41, 444-461.e4.	0.4	25
142	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2102.	1.6	71
143	Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals via K-Ras at the plasma membrane of Acute Myeloid Leukemia cells. <i>Journal of Cell Science</i> , 2013, 126, 4746-55.	2.0	23
144	SETBP1 mutation analysis in 944 patients with MDS and AML. <i>Leukemia</i> , 2013, 27, 2072-2075.	7.2	60

#	ARTICLE	IF	CITATIONS
145	Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. <i>Leukemia</i> , 2013, 27, 2068-2072.	7.2	20
146	The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. <i>Blood</i> , 2013, 122, 83-92.	1.4	169
147	Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis. <i>Case Reports in Oncology</i> , 2013, 6, 311-315.	0.7	2
148	In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice. <i>PLoS ONE</i> , 2013, 8, e60680.	2.5	22
149	Scoring Systems For Predicting Outcome Of Chronic Myeloid Leukemia In Adults Are Poorly Informative In Pediatric Patients Treated With Imatinib. <i>Blood</i> , 2013, 122, 2725-2725.	1.4	5
150	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	1.4	6
151	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 711-711.	1.4	0
152	Identification Of Novel Markers Of Human AML Stem Cells Using High Resolution Proteomics and Transcriptomics. <i>Blood</i> , 2013, 122, 4194-4194.	1.4	0
153	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial –. <i>Blood</i> , 2013, 122, 304-304.	1.4	0
154	Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. <i>Leukemia</i> , 2012, 26, 381-389.	7.2	349
155	Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leukemia: recommendations from a German expert panel. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.6	0
156	Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. <i>Haematologica</i> , 2012, 97, e34-e35.	3.5	68
157	Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2012, 93, 744-749.	1.0	47
158	Reconstitution of 6-Sulfo LacNAc Dendritic Cells After Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2012, 93, 1270-1275.	1.0	5
159	Mutant DNMT3A: teaming up to transform. <i>Blood</i> , 2012, 119, 5615-5617.	1.4	18
160	Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. <i>Acta Neuropathologica</i> , 2012, 124, 883-891.	7.7	58
161	Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. <i>Blood</i> , 2012, 120, 4205-4214.	1.4	145
162	Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. <i>Lancet Oncology</i> , The, 2012, 13, 207-214.	10.7	69

#	ARTICLE	IF	CITATIONS
163	Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. <i>Blood</i> , 2012, 119, 2346-2357.	1.4	72
164	Genomic <i>BCR-ABL1</i> breakpoints in pediatric chronic myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1045-1053.	2.8	50
165	Second Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by <i>Helicobacter pylori</i> Eradication and Followed for 10 Years. <i>Gastroenterology</i> , 2012, 143, 936-942.	1.3	60
166	Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells. <i>BMC Cancer</i> , 2012, 12, 576.	2.6	30
167	Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). <i>Annals of Hematology</i> , 2012, 91, 9-18.	1.8	73
168	Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia – A Randomised SAL Pilot Study. <i>PLoS ONE</i> , 2012, 7, e52695.	2.5	25
169	Reply to: “Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity” by Kern et al.. <i>Leukemia</i> , 2011, 25, 895-897.	7.2	3
170	Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?. <i>Haematologica</i> , 2011, 96, e31-e31.	3.5	9
171	Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. <i>Haematologica</i> , 2011, 96, 1568-1570.	3.5	67
172	Prophylactic transfer of BCR-ABL ⁺ , PR1 ⁺ , and WT1-reactive donor T cells after T cell ⁺ depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 7174-7184.	1.4	48
173	Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. <i>Leukemia</i> , 2011, 25, 420-428.	7.2	32
174	miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. <i>Experimental Hematology</i> , 2011, 39, 1030-1042.e7.	0.4	43
175	Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. <i>Leukemia Research</i> , 2011, 35, 620-625.	0.8	28
176	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML ⁺ BFM and DCOG study groups. <i>Leukemia</i> , 2011, 25, 1704-1710.	7.2	73
177	Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. <i>Leukemia</i> , 2011, 25, 880-883.	7.2	18
178	Targeted isolation of cloned genomic regions by recombineering for haplotype phasing and isogenic targeting. <i>Nucleic Acids Research</i> , 2011, 39, e137-e137.	14.5	14
179	Cytarabine Dose of 36 g/m ² Compared With 12 g/m ² Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2696-2702.	1.6	94
180	Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System. <i>Journal of Clinical Oncology</i> , 2011, 29, 2758-2765.	1.6	220

#	ARTICLE	IF	CITATIONS
181	A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial. <i>Blood</i> , 2011, 118, 497-497.	1.4	4
182	Mobilization of PML/RAR α negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide. <i>Haematologica</i> , 2010, 95, 171-172.	3.5	6
183	Pim2 cooperates with PML-RAR α to induce acute myeloid leukemia in a bone marrow transplantation model. <i>Blood</i> , 2010, 115, 4507-4516.	1.4	12
184	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010, 116, 3907-3922.	1.4	100
185	A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. <i>Blood</i> , 2010, 115, 2462-2472.	1.4	46
186	Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. <i>Blood</i> , 2010, 116, 3564-3571.	1.4	90
187	WHO classification of myeloid neoplasms and leukemia. <i>Blood</i> , 2010, 115, 748-749.	1.4	20
188	A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> , 2010, 116, 971-978.	1.4	157
189	Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. <i>Annals of Hematology</i> , 2010, 89, 653-662.	1.8	40
190	Impact of CXCR4 inhibition on FLT3-ITD $^{+}$ positive human AML blasts. <i>Experimental Hematology</i> , 2010, 38, 180-190.	0.4	36
191	¹⁸⁸ Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and <i>in vivo</i> T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 148, 910-917.	2.5	21
192	Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia. <i>Leukemia</i> , 2010, 24, 1813-1816.	7.2	22
193	General Transcription Factor Binding at CpG Islands in Normal Cells Correlates with Resistance to <i>De novo</i> DNA Methylation in Cancer Cells. <i>Cancer Research</i> , 2010, 70, 1398-1407.	0.9	107
194	Mixed Lymphohematopoietic Chimerism and Response in Wegener's Granulomatosis. <i>New England Journal of Medicine</i> , 2010, 362, 2431-2432.	27.0	6
195	Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia. <i>Haematologica</i> , 2010, 95, 852-853.	3.5	5
196	Immunohistochemical Surrogates for Genetic Alterations of CCDN1, PML, ALK, and NPM1 Genes in Lymphomas and Acute Myeloid Leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 417-431.	1.7	8
197	Genetic Variations of Interleukin-23R (1143A>G) and BPI (A645G), but Not of NOD2, Are Associated with Acute Graft-versus-Host Disease after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1718-1727.	2.0	22
198	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. <i>Lancet</i> , The, 2010, 376, 2000-2008.	13.7	290

#	ARTICLE	IF	CITATIONS
199	Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2010, 116, 3572-3581.	1.4	107
200	BPI A645G SNP but Not NOD2 Genotype Predicts for Acute Lung Injury After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2324-2324.	1.4	11
201	Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. <i>BMC Bioinformatics</i> , 2009, 10, 422.	2.6	40
202	Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. <i>American Journal of Hematology</i> , 2009, 84, 308-309.	4.1	30
203	HLA ^{DR<sup>neg</sup>} patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 321-327.	1.5	31
204	Efficient Production of Bioactive Recombinant Human Flt3 Ligand in E. coli. <i>Protein Journal</i> , 2009, 28, 57-65.	1.6	16
205	Rhinocerebral zygomycosis and subsequent treatment decisions in a young patient with AML. <i>Leukemia Research</i> , 2009, 33, e88-e90.	0.8	1
206	Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. <i>Leukemia Research</i> , 2009, 33, e215-e217.	0.8	14
207	Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 101-108.	2.0	47
208	Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. <i>Blood</i> , 2009, 113, 3568-3576.	1.4	80
209	The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. <i>Haematologica</i> , 2009, 94, 430-431.	3.5	3
210	Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1613-1617.	3.5	98
211	Risk Stratification and Prognostic Factors in Elderly AML Patients â€œ Updated Results of 909 Patients Entered Into the Prospective AML96 Trial.. <i>Blood</i> , 2009, 114, 329-329.	1.4	2
212	Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3351-3351.	1.4	2
213	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. <i>Blood</i> , 2009, 114, 480-480.	1.4	0
214	Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.. <i>Blood</i> , 2009, 114, 2652-2652.	1.4	1
215	Identification of acute myeloid leukaemia associated microRNA expression patterns. <i>British Journal of Haematology</i> , 2008, 140, 153-161.	2.5	72
216	Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis. <i>Cells Tissues Organs</i> , 2008, 188, 225-235.	2.3	31

#	ARTICLE	IF	CITATIONS
217	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008, 93, 1219-1226.	3.5	23
218	Cup-like acute myeloid leukemia: new disease or artificial phenomenon?. <i>Haematologica</i> , 2008, 93, 283-286.	3.5	38
219	Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5183-5191.	1.6	139
220	Patients With Acute Myeloid Leukemia and <i>RAS</i> Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4603-4609.	1.6	138
221	Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5585-5593.	7.0	26
222	MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. <i>Blood</i> , 2008, 111, 1855-1861.	1.4	66
223	A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2008, 112, 1490-1490.	1.4	3
224	5-azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2008, 112, 2143-2143.	1.4	3
225	Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases. <i>Blood</i> , 2008, 112, 751-751.	1.4	1
226	Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003.. <i>Blood</i> , 2008, 112, 978-978.	1.4	5
227	Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial. <i>Blood</i> , 2008, 112, 340-340.	1.4	1
228	Aberrant Intracellular Retention of Mutated Receptor Tyrosine Kinase FLT3 in Human Leukemic Cells as a Potential Mechanism Supporting the Pathogenesis of Acute Myeloid Leukaemia.. <i>Blood</i> , 2008, 112, 2245-2245.	1.4	0
229	Expression and Functional Analysis of Autotaxin, a Relevant Motility and Survival Factor, in FLT3-ITD Positive Acute Myeloid Leukemia and Primary Hematopoietic Stem Cells.. <i>Blood</i> , 2008, 112, 1206-1206.	1.4	0
230	Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. <i>Blood</i> , 2007, 109, 2264-2265.	1.4	146
231	Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. <i>Haematologica</i> , 2007, 92, 137-138.	3.5	42
232	Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. <i>Leukemia</i> , 2007, 21, 366-367.	7.2	47
233	Class I HDAC SNP analysis in healthy donors compared to AML patients. <i>Leukemia</i> , 2007, 21, 1587-1590.	7.2	4
234	A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography. <i>Journal of Pharmacological and Toxicological Methods</i> , 2007, 56, 23-27.	0.7	8

#	ARTICLE	IF	CITATIONS
235	Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients.. Blood, 2007, 110, 172-172.	1.4	1
236	Therapy of gastric mucosa associated lymphoid tissue lymphoma. World Journal of Gastroenterology, 2007, 13, 3554.	3.3	41
237	Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 2006, 107, 4011-4020.	1.4	646
238	Fast Appearance of Donor Dendritic Cells in Human Skin: Dynamics of Skin and Blood Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation. Transplantation, 2006, 81, 866-873.	1.0	38
239	Acute graft-versus-host disease of the heart. Pediatric Blood and Cancer, 2006, 47, 624-628.	1.5	17
240	Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia, 2006, 20, 437-443.	7.2	59
241	Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia, 2006, 20, 707-714.	7.2	58
242	Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia, 2006, 20, 1897-1899.	7.2	40
243	Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia, 2006, 20, 2055-2057.	7.2	7
244	Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leukemia, 2006, 20, 2188-2189.	7.2	6
245	Gene-Expression Profiling of CD34+Hematopoietic Cells Expanded in a Collagen I Matrix. Stem Cells, 2006, 24, 494-500.	3.2	78
246	Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. Gut, 2006, 55, 137-138.	12.1	61
247	BAALC Expression and FLT3 Internal Tandem Duplication Mutations in Acute Myeloid Leukemia Patients With Normal Cytogenetics: Prognostic Implications. Journal of Clinical Oncology, 2006, 24, 790-797.	1.6	158
248	Coexistence of a Heterozygous JAK2(V617F) Mutation and a Secondary BCR-ABL Translocation within the Compartment of Committed Myeloid Progenitors in Chronic Idiopathic Myelofibrosis.. Blood, 2006, 108, 4871-4871.	1.4	0
249	RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood, 2005, 105, 2107-2114.	1.4	70
250	FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 2005, 105, 4792-4799.	1.4	182
251	MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. British Journal of Haematology, 2005, 128, 324-332.	2.5	161
252	Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study. British Journal of Haematology, 2005, 128, 625-630.	2.5	35

#	ARTICLE	IF	CITATIONS
253	Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplantation, 2005, 36, 1083-1088.	2.4	4
254	Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia, 2005, 19, 161-165.	7.2	36
255	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes and Cancer, 2005, 42, 427-432.	2.8	36
256	Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Annals of Hematology, 2005, 84, 722-727.	1.8	48
257	Long-Term Follow-Up of Gastric MALT Lymphoma After <i>Helicobacter Pylori</i> Eradication. Journal of Clinical Oncology, 2005, 23, 8018-8024.	1.6	289
258	Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts. Clinical Cancer Research, 2005, 11, 3217-3224.	7.0	45
259	Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation.. Blood, 2005, 106, 224-224.	1.4	5
260	Expression profiling of gastric cancer samples by oligonucleotide microarray analysis reveals low degree of intra-tumor variability. World Journal of Gastroenterology, 2005, 11, 5993.	3.3	14
261	Loss of Heterozygosity Identified in Acute Myeloid Leukemia with Normal Karyotype Using SNP Microarrays.. Blood, 2005, 106, 760-760.	1.4	0
262	MLL-PTD as a marker for minimal residual disease studies: quantification counts. Haematologica, 2005, 90, 865B.	3.5	0
263	Chimerism analysis after allogeneic stem cell transplantation. Haematologica, 2005, 90, 1301A.	3.5	3
264	Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells: down-regulation upon myeloid differentiation. Journal of Leukocyte Biology, 2004, 76, 1057-1065.	3.3	43
265	Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation â€“ a retrospective analysis. Bone Marrow Transplantation, 2004, 33, 483-490.	2.4	18
266	CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2004, 34, 949-954.	2.4	12
267	Evaluation of STR informativity for chimerism testing â€“ comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia, 2004, 18, 248-254.	7.2	71
268	Diagnostic Chimerism Analysis After Allogeneic Stem Cell Transplantation. Molecular Diagnosis and Therapy, 2004, 4, 177-187.	3.3	65
269	Strategies and Clinical Implications of Chimerism Diagnostics after Allogeneic Hematopoietic Stem Cell Transplantation. Acta Haematologica, 2004, 112, 16-23.	1.4	57
270	Hematopoietic stem cell transplantation for complete IFN- γ receptor 1 deficiency: A multi-institutional survey. Journal of Pediatrics, 2004, 145, 806-812.	1.8	92

#	ARTICLE	IF	CITATIONS
271	Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 1397-9.	3.5	28
272	Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. <i>Annals of Hematology</i> , 2003, 82, 47-52.	1.8	11
273	Etiology and therapy of <i>Helicobacter pylori</i> -associated gastric lymphomas. <i>Annals of Hematology</i> , 2003, 82, 535-545.	1.8	17
274	Evidence for a graft-versus-tumor effect in refractory ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 12-16.	2.5	9
275	Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 237-251.	2.8	133
276	Immunophenotyping is an independent factor for risk stratification in AML. <i>Cytometry</i> , 2003, 53B, 11-19.	1.8	44
277	Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 1093-1094.	2.5	4
278	Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 611-614.	2.4	5
279	HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34+ measurements and timing of leukaphereses. <i>Cytotherapy</i> , 2003, 5, 414-419.	0.7	20
280	Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 2747-2753.	1.6	238
281	B-cell Monoclonality Is Associated With Lymphoid Follicles in Gastritis. <i>American Journal of Surgical Pathology</i> , 2003, 27, 882-887.	3.7	32
282	Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. <i>Blood</i> , 2003, 102, 646-651.	1.4	123
283	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	1.4	190
284	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. <i>Blood</i> , 2002, 99, 4326-4335.	1.4	1,550
285	<i>Helicobacter</i> and gastric MALT lymphoma. <i>Gut</i> , 2002, 50, iii19-iii24.	12.1	176
286	Correction of complete interferon- γ receptor 1 deficiency by bone marrow transplantation. <i>Blood</i> , 2002, 100, 4234-4235.	1.4	42
287	Bedeutung der <i>Helicobacter-pylori</i> -Infektion für die Pathogenese und Therapie von MALT-Lymphomen des Magens. <i>Visceral Medicine</i> , 2002, 18, 24-28.	1.3	0
288	T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to <i>H. pylori</i> eradication. <i>Gastroenterology</i> , 2002, 122, 1286-1294.	1.3	397

#	ARTICLE	IF	CITATIONS
289	Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2002, 69, 7-10.	2.2	9
290	Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. <i>Haematologica</i> , 2002, 87, 299-305.	3.5	31
291	Molecular Diagnostics in Low-Grade Gastric Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type After <i>Helicobacter pylori</i> Eradication Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 103-108.	2.1	8
292	Determination of Mycophenolic Acid and Mycophenolate Mofetil by High-Performance Liquid Chromatography Using Postcolumn Derivatization. <i>Analytical Chemistry</i> , 2001, 73, 41-46.	6.5	38
293	Complete Remission of Primary High-Grade B-Cell Gastric Lymphoma After Cure of <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Oncology</i> , 2001, 19, 2041-2048.	1.6	184
294	Long-Term Persistence of Monoclonal B Cells After Cure of <i>Helicobacter pylori</i> Infection and Complete Histologic Remission in Gastric Mucosa-Associated Lymphoid Tissue B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1600-1609.	1.6	119
295	SUCCESSFUL PREEMPTIVE CIDOFOVIR TREATMENT FOR CMV ANTIGENEMIA AFTER DOSE-REDUCED CONDITIONING AND ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION. <i>Transplantation</i> , 2001, 71, 880-885.	1.0	40
296	Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. <i>Annals of Hematology</i> , 2001, 80, 144-149.	1.8	20
297	Long-term follow-up of gastric malt lymphoma after <i>H. pylori</i> eradication. <i>Current Gastroenterology Reports</i> , 2001, 3, 516-522.	2.5	26
298	Mutations in ras proto-oncogenes are associated with lower <i>mdr1</i> gene expression in adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001, 112, 300-307.	2.5	52
299	Are lymphocytic monoclonality and immunoglobulin heavy chain (IgH) rearrangement premalignant conditions in chronic gastritis?. <i>Microscopy Research and Technique</i> , 2001, 53, 414-418.	2.2	4
300	Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. <i>Bone Marrow Transplantation</i> , 2001, 27, 107-109.	2.4	23
301	Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. <i>Leukemia</i> , 2001, 15, 293-302.	7.2	208
302	Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. <i>Cancer Genetics and Cytogenetics</i> , 2001, 127, 111-117.	1.0	15
303	Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2001, 27, 543-546.	2.4	17
304	Somatic hypermutation and B-cell lymphoma. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 73-82.	4.0	33
305	Development of early gastric cancer 4 and 5 years after complete remission of <i>Helicobacter pylori</i> associated gastric low grade marginal zone B cell lymphoma of MALT type. <i>World Journal of Gastroenterology</i> , 2001, 7, 248.	3.3	60
306	Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated ?enriched PCR? protocol. , 2000, 190, 69-75.		31

#	ARTICLE	IF	CITATIONS
307	Forum: Letters to the Editor. Cytometry, 2000, 42, 396-397.	1.8	10
308	Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplantation, 2000, 26, 119-125.	2.4	73
309	Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 2000, 14, 1031-1038.	7.2	61
310	Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approach. Leukemia, 2000, 14, 1850-1856.	7.2	33
311	Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplantation, 2000, 25, 575-577.	2.4	131
312	Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood, 2000, 95, 4014-4015.	1.4	114
313	Lack of Point Mutations in Exons 11-23 of the Retinoblastoma Susceptibility Gene RB-1 in Liver Metastases of Colorectal Carcinoma. Oncology, 2000, 59, 344-346.	1.9	3
314	Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: Complete remission after curing the infection. Gastroenterology, 2000, 118, 821-828.	1.3	270
315	Eradication of Helicobacter pylori and Stability of Remissions in Low-Grade Gastric B-Cell Lymphomas of the Mucosa-Associated Lymphoid Tissue: Results of an Ongoing Multicenter Trial. Recent Results in Cancer Research, 2000, 156, 125-133.	1.8	55
316	Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplantation, 1999, 23, 1055-1060.	2.4	243
317	Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer, 1999, 85, 1664-1669.	4.1	2
318	MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION. Transplantation, 1999, 67, 499-504.	1.0	99
319	STABLE ENGRAFTMENT AFTER MEGADOSE BLOOD STEM CELL TRANSPLANTATION ACROSS THE HLA BARRIER. Transplantation, 1999, 68, 87-88.	1.0	24
320	bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. European Journal of Cancer, 1998, 34, 1268-1273.	2.8	21
321	Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. Journal of Clinical Oncology, 1998, 16, 3822-3831.	1.6	56
322	Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias. Blood, 1998, 91, 22-29.	1.4	188
323	Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias. Blood, 1998, 91, 22-29.	1.4	11
324	Cure of Helicobacter pylori Infection and Duration of Remission of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of the National Cancer Institute, 1997, 89, 1350-1355.	6.3	296

#	ARTICLE	IF	CITATIONS
325	Focal Inflammatory Infiltrations in Gastric Biopsy Specimens Are Suggestive of Crohn's Disease. Scandinavian Journal of Gastroenterology, 1997, 32, 813-818.	1.5	50
326	Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology, 1997, 113, 1087-1090.	1.3	299
327	The status of p53 in the metastatic progression of colorectal cancer. European Journal of Cancer, 1997, 33, 1314-1322.	2.8	24
328	What Role Does Helicobacter pylori Eradication Play in Gastric MALT and Gastric MALT Lymphoma?. Gastroenterology, 1997, 113, S61-S64.	1.3	85
329	Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma?. Journal of Clinical Oncology, 1997, 15, 1104-1109.	1.6	51
330	Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. British Journal of Haematology, 1997, 98, 969-972.	2.5	46
331	MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. Journal of Cancer Research and Clinical Oncology, 1996, 122, 671-675.	2.5	22
332	Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Research, 1996, 24, 4102-4103.	14.5	28
333	Simple and Sensitive Detection of Mutations in the Ras Proto-Oncogenes Using PNA-Mediated PCR Clamping. Nucleic Acids Research, 1996, 24, 983-984.	14.5	113
334	Simple and Rapid Detection of Factor V Leiden by Allele-specific PCR Amplification. Thrombosis and Haemostasis, 1996, 75, 757-759.	3.4	16
335	Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Annals of Oncology, 1995, 6, 981-986.	1.2	11
336	Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet, The, 1995, 345, 1591-1594.	13.7	927
337	Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. British Journal of Cancer, 1994, 70, 1267-1271.	6.4	23